Product Images Tafinlar

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Tafinlar NDC 0078-0682 by Novartis Pharmaceuticals Corporation, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

The following chemical structure for Dabrafenib mesylate is a kinase inhibitor. The chemical name for dabrafenib mesylate is N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene sulfonamide, methanesulfonate salt. It has the molecular formula C23H20F3N5O2S2•CH4O3S and a molecular weight of 615.68. - tafinlar 01

Figure 1. Kaplan-Meier Curves of Investigator-Assessed Progression-Free Survival in the BREAK-3 Study - tafinlar 02

Figure 2. Kaplan-Meier Curves for Overall Survival in the COMBI-d Study - tafinlar 03

Figure 3. Kaplan-Meier Curves for Overall Survival in the COMBI-v Study - tafinlar 04

PRINCIPAL DISPLAY PANEL - tafinlar 05

Each capsule contains 88.88 mg of dabrafenib mesylate, indicated for the treatment of patients with melanoma with BRAF V600E mutation as detected by an FDA-approved test. It is recommended to store the capsules at room temperature ranging from 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Dosage information is available in the accompanying USP Controlled Room Temperature label. The product is distributed by Hours Pharmaceuticals and manufactured in Singapore. Novartis owns the product trademark Tafinlar®.*

PRINCIPAL DISPLAY PANEL - tafinlar 06

This is a description of a medication called Dabrafenib Mesylate, which is available in capsules. Each capsule contains 59.25mg of the medication and should be stored at 20°C to 25°C (68°F to 77°F). It is equivalent to Afiniar and the dosage is S 50 MG. The container has a safety seal that should not be broken or missing. The information can be found on the packaging with the NDC number 0078-0682-66. The medication is manufactured by Novartis.*

tafinlar 07

This appears to be a table or graph that shows the proportion of subjects who were alive and did not have a relapse over time, comparing a treatment with "TAFINLAR + MEKINIST" to a placebo. The table includes different time points (in months) and the number of subjects at risk at each time point. The graph shows the proportion of subjects over time for both treatment groups. The text does not provide any additional information regarding the context of the study or the conditions being treated.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.